| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2898229 | Cardiology Clinics | 2008 | 9 Pages |
Abstract
Aliskiren, the first in a new class of orally effective direct renin inhibitors (DRIs) was recently approved for the treatment of hypertension. In this review, we discuss the history of the development of DRIs and available data regarding the effects of DRIs in the treatment of hypertension and related target organ damage.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Eduardo MD, Suzanne MD,